Register Today Menu

"On the other hand, we denounce with righteous indignation and dislike men who are so beguiled and demoralized by the charms of pleasure of the moment, so blinded by desire, that they cannot foresee the pain and trouble that are bound to ensue; and equal blame belongs to those who fail in their duty through weakness of will, which is the same as saying through shrinking from toil and pain. These cases are perfectly simple and easy to distinguish. In a free hour, when our power of choice is untrammelled and when nothing prevents our being able to do what we like best, every pleasure is to be welcomed and every pain avoided. But in certain circumstances and owing to the claims of duty or the obligations of business it will frequently occur that pleasures have to be repudiated and annoyances accepted. The wise man therefore always holds in these matters to this principle of selection: he rejects pleasures to secure other greater pleasures, or else he endures pains to avoid worse pains."

"At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt mollitia animi, id est laborum et dolorum fuga. Et harum quidem rerum facilis est et expedita distinctio. Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime placeat facere possimus, omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis aut rerum necessitatibus saepe eveniet ut et voluptates repudiandae sint et molestiae non recusandae. Itaque earum rerum hic tenetur a sapiente delectus, ut aut reiciendis voluptatibus maiores alias consequatur aut perferendis doloribus asperiores repellat."

Simbec-Orion Clinical Pharmacology will soon be running a two part study to investigate a drug called MB272.

The overall objectives of the study are to determine the safety, tolerability and concentration in the blood of the study drug when evaluated in different conditions i.e., different dose strengths, following administration of single and multiple doses, and following administration in two different forms.

The study also aims to evaluate the effect of the study drug on the body, through the collection of blood samples at different times through the day.

Simbec-Orion Clinical Pharmacology will soon be running a two part study to investigate a drug called MB272.

The overall objectives of the study are to determine the safety, tolerability and concentration in the blood of the study drug when evaluated in different conditions i.e., different dose strengths, following administration of single and multiple doses, and following administration in two different forms.

The study also aims to evaluate the effect of the study drug on the body, through the collection of blood samples at different times through the day.

Simbec-Orion Clinical Pharmacology will soon be running a two part study to investigate a drug called MB272.

The overall objectives of the study are to determine the safety, tolerability and concentration in the blood of the study drug when evaluated in different conditions i.e., different dose strengths, following administration of single and multiple doses, and following administration in two different forms.

The study also aims to evaluate the effect of the study drug on the body, through the collection of blood samples at different times through the day.

"Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?"

"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum."

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

"On the other hand, we denounce with righteous indignation and dislike men who are so beguiled and demoralized by the charms of pleasure of the moment, so blinded by desire, that they cannot foresee the pain and trouble that are bound to ensue; and equal blame belongs to those who fail in their duty through weakness of will, which is the same as saying through shrinking from toil and pain. These cases are perfectly simple and easy to distinguish. In a free hour, when our power of choice is untrammelled and when nothing prevents our being able to do what we like best, every pleasure is to be welcomed and every pain avoided. But in certain circumstances and owing to the claims of duty or the obligations of business it will frequently occur that pleasures have to be repudiated and annoyances accepted. The wise man therefore always holds in these matters to this principle of selection: he rejects pleasures to secure other greater pleasures, or else he endures pains to avoid worse pains."

Posts list

If you are a healthy male or female aged between 18 and 55 with a known peanut allergy, you may be eligible to participate in a study investigating a new drug being developed for the potential treatment of severe allergic reactions.

Study Payment* £2,050.

Apply for this study

*Terms & Conditions apply.

Study Payment: £2050

"*" indicates required fields

Step 1 of 3

33%

This field is hidden when viewing the form

Advertising Source

* indicates a required field

By agreeing to this form and selecting the box as outlined below, you are confirming that you have read the information provided in our data protection and consent policy, and give your consent for Simbec-Orion to record and retain your personal and special categories of data for the purposes and duration(s) stated in our policy linked above.

Simbec-Orion are also required to process your bio-metric data (a photograph only when you attend an onsite screening visit), we do this to ensure we can identify you for security purposes. We do not share this data with any other third-party, we solely use this data for the purpose of recognition. For the completion of your enrolment and part of your eligibility, we are required to collect this data. By selecting the box below, you also explicitly consent to the use of your bio-metric data as and when it is collected.

Agreement*

I understand and wish to proceed

* indicates a required field

Do you have a peanut allergy diagnosed by a healthcare professional, and would be willing to undergo an allergy test at the screening visit?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this part of the study.

Please check out our other studies to see if you may be eligible to apply for one of those.

Have you ever suffered from a serious allergic reaction or have a known severe allergy other than peanuts?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this part of the study.

Please check out our other studies to see if you may be eligible to apply for one of those.

Are you currently using some form of contraception?*

Which of the following best describes you or your contraceptive status?Combined (oestrogen and progestogen containing) hormonal contraception (oral, intravaginal and transdermal) associated with inhibition of ovulationProgestogen-only hormonal contraception (oral, injectable and implantable) associated with inhibition of ovulationIntrauterine device (IUD)Intrauterine hormone-releasing system (IUS)Barrier Method (Male or female condom with or without spermicide or cap, diaphragm or sponge with spermicide)Bilateral tubal occlusionVasectomyHysterectomyPost-menopausalVasectomised partnerSterile partner (via hysterectomy or tubal occlusion)Sexual abstinence (refraining from heterosexual intercourse as the preferred and usual lifestyle choice)None of the above

Unfortunately to participate in a clinical study you must be willing to use a listed contraceptive method prior to being enrolled in the study

Please check out our other studies to see if you may be eligible to apply for one of those.

Are you registered with a General Practitioner (GP) , and have been for the last 12 months?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to register at this time.

You need to be registered with a GP for at least 3 months in order to participate in a clinical trial. This is to ensure your safety, and your past medical history can be safely evaluated from your GP to assess your suitability for each and every trial.

Have you been diagnosed or tested positive for Coronavirus/COVID-19 within the last month?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply at this time.

Have you received a COVID-19 vaccine or any other type of vaccine within the last 35 days?*

Yes

No

If yes, please give details of vaccine, including the date

Do you suffer from or ever had any serious illnesses as diagnosed by your GP or health professional?*

Yes

No

(e.g., neurological, endocrinal, cardiovascular, pulmonary, haematological, immunologic, psychiatric, gastrointestinal, renal, hepatic and metabolic disease)

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

Please check out our other studies to see if you may be eligible to apply for one of those.

Do you suffer from/have a history of gastro-intestinal conditions or surgeries within the last 12 weeks?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

Are you taking any prescription or repeat medication from a GP or a chemist*

Yes

No

(including epi-pen, inhalers, over-the-counter medications, and vitamins or supplements)

If yes, please give details*

Do you regularly use illegal drugs?*

Yes

No

(i.e., Substances that are used for non-medicinal and leisure purposes. We test as part of the screening procedures.)

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply at this time.

Have you completed any other studies in the last 3months?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

Have you experienced an allergic reaction which required hospitalisation in the last 30 days?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

Do you smoke or use any nicotine products (including vapes and eCigarettes)?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

Have you smoked or used any nicotine products within the last 3 months?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

Have you donated, given or lost more than 450ml of blood/blood products in the last 12 weeks?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

Do you drink alcohol?*

Yes

No

Do you consume more than 14 units per week?*

Yes

No

(For example, a can of beer/cider/lager is approximately 2 units)

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

Have you had any body piercings (including your mouth lips or cheeks) or tattoos in the last 3 months?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

* indicates a required field

Your details

First Name*

Last Name*

Gender at Birth

Please select your gender at birthMaleFemale

Date of Birth*

DayDay12345678910111213141516171819202122232425262728293031

MonthMonth123456789101112

YearYear202720262025202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986198519841983198219811980197919781977197619751974197319721971197019691968196719661965196419631962196119601959195819571956195519541953195219511950194919481947194619451944194319421941194019391938193719361935193419331932193119301929192819271926192519241923192219211920

This field is hidden when viewing the form

Age

Height*

Please select your height below4 foot 8 (142cm)4 foot 9 (145cm)4 foot 10 (147cm)4 foot 11 (150cm)5 foot (152cm)5 foot 1 (155cm)5 foot 2 (157cm)5 foot 3 (160cm)5 foot 4 (163cm)5 foot 5 (165cm)5 foot 6 (168cm)5 foot 7 (170cm)5 foot 8 (173cm)5 foot 9 (175cm)5 foot 10 (178cm)5 foot 11 (180cm)6 foot (183cm)6 foot 1 (185cm)6 foot 2 (188cm)6 foot 3 (191cm)6 foot 4 (193cm)6 foot 5 (196cm)6 foot 6 (198cm)6 foot 7 (201cm)6 foot 8 (203cm)6 foot 9 (206cm)6 foot 10 (208cm)6 foot 11 (211cm)7 foot (213cm)

Weight*

Please select your weight below7 stone, 12 lb / 49.90 kg7 stone, 13 lb / 50.35 kg8 stone, 0 lb / 50.80 kg8 stone, 1 lb / 51.26 kg8 stone, 2 lb / 51.71 kg8 stone, 3 lb / 52.16 kg8 stone, 4 lb / 52.62 kg8 stone, 5 lb / 53.07 kg8 stone, 6 lb / 53.52 kg8 stone, 7 lb / 53.98 kg8 stone, 8 lb / 54.43 kg8 stone, 9 lb / 54.88 kg8 stone, 10 lb / 55.34 kg8 stone, 11 lb / 55.79 kg8 stone, 12 lb / 56.25 kg8 stone, 13 lb / 56.70 kg9 stone, 0 lb / 57.15 kg9 stone, 1 lb / 57.61 kg9 stone, 2 lb / 58.06 kg9 stone, 3 lb / 58.51 kg9 stone, 4 lb / 58.97 kg9 stone, 5 lb / 59.42 kg9 stone, 6 lb / 59.87 kg9 stone, 7 lb / 60.33 kg9 stone, 8 lb / 60.78 kg9 stone, 9 lb / 61.23 kg9 stone, 10 lb / 61.69 kg9 stone, 11 lb / 62.14 kg9 stone, 12 lb / 62.60 kg9 stone, 13 lb / 63.05 kg10 stone, 0 lb / 63.50 kg10 stone, 1 lb / 63.96 kg10 stone, 2 lb / 64.41 kg10 stone, 3 lb / 64.86 kg10 stone, 4 lb / 65.32 kg10 stone, 5 lb / 65.77 kg10 stone, 6 lb / 66.22 kg10 stone, 7 lb / 66.68 kg10 stone, 8 lb / 67.13 kg10 stone, 9 lb / 67.59 kg10 stone, 10 lb / 68.04 kg10 stone, 11 lb / 68.49 kg10 stone, 12 lb / 68.95 kg10 stone, 13 lb / 69.40 kg11 stone, 0 lb / 69.85 kg11 stone, 1 lb / 70.31 kg11 stone, 2 lb / 70.76 kg11 stone, 3 lb / 71.21 kg11 stone, 4 lb / 71.67 kg11 stone, 5 lb / 72.12 kg11 stone, 6 lb / 72.57 kg11 stone, 7 lb / 73.03 kg11 stone, 8 lb / 73.48 kg11 stone, 9 lb / 73.94 kg11 stone, 10 lb / 74.39 kg11 stone, 11 lb / 74.84 kg11 stone, 12 lb / 75.30 kg11 stone, 13 lb / 75.75 kg12 stone, 0 lb / 76.20 kg12 stone, 1 lb / 76.66 kg12 stone, 2 lb / 77.11 kg12 stone, 3 lb / 77.56 kg12 stone, 4 lb / 78.02 kg12 stone, 5 lb / 78.47 kg12 stone, 6 lb / 78.93 kg12 stone, 7 lb / 79.38 kg12 stone, 8 lb / 79.83 kg12 stone, 9 lb / 80.29 kg12 stone, 10 lb / 80.74 kg12 stone, 11 lb / 81.19 kg12 stone, 12 lb / 81.65 kg12 stone, 13 lb / 82.10 kg13 stone, 0 lb / 82.55 kg13 stone, 1 lb / 83.01 kg13 stone, 2 lb / 83.46 kg13 stone, 3 lb / 83.91 kg13 stone, 4 lb / 84.37 kg13 stone, 5 lb / 84.82 kg13 stone, 6 lb / 85.28 kg13 stone, 7 lb / 85.73 kg13 stone, 8 lb / 86.18 kg13 stone, 9 lb / 86.64 kg13 stone, 10 lb / 87.09 kg13 stone, 11 lb / 87.54 kg13 stone, 12 lb / 88.00 kg13 stone, 13 lb / 88.45 kg14 stone, 0 lb / 88.90 kg14 stone, 1 lb / 89.36 kg14 stone, 2 lb / 89.81 kg14 stone, 3 lb / 90.26 kg14 stone, 4 lb / 90.72 kg14 stone, 5 lb / 91.17 kg14 stone, 6 lb / 91.63 kg14 stone, 7 lb / 92.08 kg14 stone, 8 lb / 92.53 kg14 stone, 9 lb / 92.99 kg14 stone, 10 lb / 93.44 kg14 stone, 11 lb / 93.89 kg14 stone, 12 lb / 94.35 kg14 stone, 13 lb / 94.80 kg15 stone, 0 lb / 95.25 kg15 stone, 1 lb / 95.71 kg15 stone, 2 lb / 96.16 kg15 stone, 3 lb / 96.62 kg15 stone, 4 lb / 97.07 kg15 stone, 5 lb / 97.52 kg15 stone, 6 lb / 97.98 kg15 stone, 7 lb / 98.43 kg15 stone, 8 lb / 98.88 kg15 stone, 9 lb / 99.34 kg15 stone, 10 lb / 99.79 kg15 stone, 11 lb / 100.24 kg15 stone, 12 lb / 100.70 kg15 stone, 13 lb / 101.15 kg16 stone, 0 lb / 101.60 kg16 stone, 1 lb / 102.06 kg16 stone, 2 lb / 102.51 kg16 stone, 3 lb / 102.97 kg16 stone, 4 lb / 103.42 kg16 stone, 5 lb / 103.87 kg16 stone, 6 lb / 104.33 kg16 stone, 7 lb / 104.77 kg16 stone, 8 lb / 105.23 kg16 stone, 9 lb / 105.68 kg16 stone, 10 lb / 106.14 kg16 stone, 11 lb / 106.59 kg16 stone, 12 lb / 107.04 kg16 stone, 13 lb / 107.5 kg17 stone, 0 lb / 107.95 kg17 stone, 1 lb / 108.4 kg17 stone, 2 lb / 108.86 kg17 stone, 3 lb / 109.31 kg17 stone, 4 lb / 109.76 kg17 stone, 5 lb / 110.22 kg17 stone, 6 lb / 110.67 kg17 stone, 7 lb / 111.13 kg17 stone, 8 lb / 111.58 kg17 stone, 9 lb / 112.03 kg17 stone, 10 lb / 112.49 kg17 stone, 11 lb / 112.94 kg17 stone, 12 lb / 113.39 kg17 stone, 13 lb / 113.85 kg18 stone, 0 lb / 114.3 kg18 stone, 1 lb / 114.75 kg18 stone, 2 lb / 115.21 kg18 stone, 3 lb / 115.66 kg18 stone, 4 lb / 116.11 kg18 stone, 5 lb / 116.57 kg18 stone, 6 lb / 117.02 kg18 stone, 7 lb / 117.48 kg18 stone, 8 lb / 117.93 kg18 stone, 9 lb / 118.38 kg18 stone, 10 lb / 118.84 kg18 stone, 11 lb / 119.29 kg18 stone, 12 lb / 119.74 kg18 stone, 13 lb / 120.2 kg19 stone, 0 lb / 120.65 kg19 stone, 1 lb / 121.1 kg19 stone, 2 lb / 121.56 kg19 stone, 3 lb / 122.01 kg19 stone, 4 lb / 122.46 kg

Your BMI

Your BMI

This field is hidden when viewing the form

BMI Calc

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

Race*

Please select your race belowAmerican Indian or Alaska NativeAsianBlack or African AmericanNative Hawaiian or Other Pacific IslanderWhiteUnknownOther Race (please state below)

Your Race*

Street Address*

City*

Postcode*

Phone Number*

Email*

Can we contact you by email?

Yes

Can we contact you by SMS?

Yes

Can we contact you by phone?

Yes

Please select at least one contact mechanism to facilitate your participation in future clinical studies.

Study Testimonial

“I had quite a few staff to support and watch over me while undergoing the peanut challenge, which was comforting and I knew that I was in safe hands throughout the process.”

From Our First Volunteer Dosed

Study Information

Simbec-Orion Clinical Pharmacology, out of our Merthyr Tydfil facility, will soon be running a study to investigate the study drug, P2-101 (active ingredient adrenaline in the form of tablet which dissolves under the tongue) in comparison with the very common injectable form of adrenaline (administered as an injection directly into the muscle) used in the treatment of severe allergic reactions (such as Anaphylaxis) and a placebo treatment (containing no active study drug).

The main objectives of the study are as follows: 

• To evaluate the effectiveness of P2-101 when it is administered as a single dose on one occasion, in comparison with an adrenaline injection and a placebo treatment. 

• To investigate the effect of P2-101 on the body through the measurement of specific safety parameters e.g., vital signs, heart activity monitoring and blood sugars. 

• To evaluate the general safety, tolerability of P2-101 when it is administered as a single dose on one occasion, in comparison with an adrenaline injection and a placebo treatment.

• To investigate the concentration of P2-101 in the blood, how this changes over time and to evaluate whether the concentration of P2-101 is similar to the concentration observed in the blood for injectable adrenaline following administration of single doses

Blood samples and other measures as described will be taken at set time points throughout the study to measure the effectiveness of P2-101 in comparison with the adrenaline injection. In the context of the whole study, we will analyse the results from each of the treatment periods and combine this information in order to better understand how P2-101 works in the body and to determine how comparably effective P2-101 is when used in the treatment of allergic reaction. The purpose of the data generated in this study is to provide further information and guidance to support the study Sponsor in the development of the study drug, P2-101

P2-101 is being developed for the treatment of severe allergic reactions. Currently, there are multiple injectable forms of adrenaline available which are used in the treatment of severe allergic reactions and anaphylaxis including systems such as EpiPen®; however, these are not always the easiest of products to use and are often expensive so are not accessible to all individuals who may require this type of product to manage their condition. Therefore, there is an unmet need to develop potential new formulations of adrenaline which could be more effective and reduce these challenges.

If you require any further information or would like to speak with a member of the team before applying please see contact details at the bottom of this page. On successful application you will receive the full clinical study information sheet and consent form, to aid any questions and queries you may have about participating in this trial.

Ready? Let’s get started

Purpose and Timeline

The purpose of the study is to evaluate the study objectives when P2-101, an adrenaline injection and a placebo treatment are administered as single doses across two treatment periods. The study will consist of up to 12 participants who have a known peanut allergy (documented within the last 12 months and confirmed via allergy testing at screening) with a minimum of 10 participants required to complete both treatment periods

Across the two treatment periods, each participant will receive:

• A single dose of P2-101 (15 milligrams (mg)) in the form of a sublingual tablet (tablet which is placed under the tongue and dissolves naturally) with a placebo injection (containing no study drug).

• A single dose of injectable adrenaline (0.3 mg) with a placebo sublingual tablet.

Prior to dose administration in each treatment period, participants will be required to undertake a food challenge whereby they will be asked to eat a food product containing peanuts (e.g., peanut cookies or peanut powder as a paste in natural yoghurt) to trigger an allergic reaction.

Stay Requirements

If you participate in this study, you will be required to stay at the Simbec-Orion clinical unit
for a maximum period of 2 days (1 overnight stay) per treatment period for a maximum of two treatment periods.

Visits

If you participate in this study, you will be required complete the study visits at the clinical unit as follows:

• One Screening Visit – Within 35 days of treatment period one.

• Two Treatment Periods – Day -1 to Day 1 (one overnight stay, two days overall duration). Each dose in each treatment period will be separated by a period of
  at least 7 days

You should ensure that you are able to commit to completing all visits before agreeing to participate in this study.

Study Payment

If you participate in this part of the study, you will receive an inconvenience payment for the inconvenience of participating in and satisfactorily completing the study including all procedures and the post-study follow up visit, along with the highest level of compliance.

• Screening Visit: £100
• Total Inconvenience Payment: £2050
• Travel Expenses: £75 (per visit)

Screening Visit
Day -35 to Day -2

Treatment Period One

Day -1 (admission) to Day 1 (discharge).

Treatment Period Two

Day -1 (admission) to Day 1 (discharge)

Post Study Follow-up Telephone Call

5 to 7 days following you last dose.

Apply Now. Be Amazing

1914 translation by H. Rackham

06/12/2023

“On the other hand, we denounce with righteous indignation and dislike men who are so beguiled and demoralized by the charms of pleasure of the moment, so blinded by desire, that they cannot foresee the pain and trouble that are bound to ensue; and equal blame belongs to those who fail in their duty through […]

Read

Section 1.10.33 of “de Finibus Bonorum et Malorum”, written by Cicero in 45 BC

06/12/2023

“At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt mollitia animi, id est laborum et dolorum fuga. Et harum quidem rerum facilis est et expedita distinctio. Nam libero tempore, […]

Read

News item from Simbec-Orion

06/12/2023

Simbec-Orion Clinical Pharmacology will soon be running a two part study to investigate a drug called MB272. The overall objectives of the study are to determine the safety, tolerability and concentration in the blood of the study drug when evaluated in different conditions i.e., different dose strengths, following administration of single and multiple doses, and […]

Read

Section 1.10.32 of “de Finibus Bonorum et Malorum”, written by Cicero in 45 BC

06/12/2023

“Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque […]

Read

The standard Lorem Ipsum passage, used since the 1500s

06/12/2023

“Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat […]

Read

What is Lorem Ipsum?

05/12/2023

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into […]

Read